Table 2.
Univariate and multivariate analyses of patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin with respect to VR and NVR
| Variable | Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|---|
| VR (133) | NVR (69) | P value | B | P value | Odds ratio | 95% CI | |
| Gender (Male/Female) | 74/59 | 38/31 | 1.000 | ||||
| Age (years) | 58 ± 11 (133) | 59 ± 11 (69) | 0.973 | ||||
| Body weight (kg) | 59.9 ± 11.5 (130) | 59.7 ± 11.6 (68) | 0.992 | ||||
| Hx. of IFN treatment (naïve/experienced) | 108/25 | 52/17 | 0.363 | ||||
| PEG-IFN-α2a/-α2b | 18/115 | 12/57 | 0.533 | ||||
| Albumin (g/dL) | 4.2 ± 0.5 (133) | 4.0 ± 0.4 (67) | 0.148 | 0.118 | 0.036 | 1.125 | 1.008–1.256 |
| AST (U/L) | 52 ± 34 (133) | 70 ± 50 (69) | 0.022 | −0.001 | 0.919 | 0.999 | 0.983–1.016 |
| ALT (U/L) | 66 ± 47 (133) | 81 ± 64 (69) | 0.244 | ||||
| T.Bil (mg/dL) | 0.88 ± 0.32 (129) | 0.81 ± 0.35 (69) | 0.085 | 0.102 | 0.083 | 1.108 | 0.987–1.243 |
| ALP (U/L) | 258 ± 80 (133) | 273 ± 109 (69) | 0.378 | ||||
| γ-GTP (U/L) | 45 ± 43 (133) | 75 ± 95 (69) | < 0.001 | −0.002 | 0.508 | 0.998 | 0.991–1.005 |
| T.Chol (mg/dL) | 172 ± 39 (130) | 161 ± 32 (66) | 0.016 | 0.004 | 0.556 | 1.004 | 0.991–1.017 |
| HCV RNA (Log IU/mL) | 6.5 ± 0.6 (133) | 6.6 ± 0.5 (69) | 0.384 | ||||
| WBC (/μL) | 4982 ± 1248 (133) | 4784 ± 1271(69) | 0.275 | ||||
| Hemoglobin (g/dL) | 13.9 ± 1.2 (133) | 13.7 ± 1.8 (69) | 0.308 | ||||
| Platelets (× 104/μL) | 17.0 ± 5.9 (133) | 16.0 ± 5.0 (69) | 0.377 | ||||
| FIB-4 index | 2.7 ± 1.7 (133) | 3.1 ± 1.8 (69) | 0.035 | 0.055 | 0.755 | 1.056 | 0.749–1.490 |
| Core 70 amino acid (wild/mutant) | 93/37 | 23/45 | < 0.001 | −0.914 | 0.029 | 0.401 | 0.177–0.910 |
| Core 91 amino acid (wild/mutant) | 92/38 | 42/26 | 0.205 | ||||
| ISDR mutation (n = 0–1/2-) | 108/20 | 59/8 | 0.528 | ||||
| rs8099917 (TT/non-TT) | 117/16 | 25/44 | < 0.001 | −2.735 | < 0.001 | 0.065 | 0.025–0.171 |
| (TA)n (n = 11–12/13–18) | 85/48 | 53/16 | 0.079 | −1.226 | 0.011 | 0.294 | 0.114–0.757 |
| PEG-IFN adherence (%) | 95.5 ± 10.3 (132) | 89.7 ± 17.3 (64) | 0.093 | ||||
| Ribavirin adherence (%) | 94.8 ± 10.9 (133) | 90.3 ± 17.7 (64) | 0.232 | ||||
Data are shown as mean ± standard deviation. Figures in parentheses are the numbers of data available in each variable. Multivariate and simultaneous logistic regression analysis was performed to determine predictive factors for NVR, by using nine variables which were found to be P < 0.150 by univariate analysis (albumin, AST, T.Bil, γ-GTP, T.Chol, fib-4 index, Core 70 amino acid, rs8099917, (TA)n). In addition, PEG-IFN adherence and ribavirin adherence were excluded from this analysis, since these two variables could not be available at pretreatment. The corresponding references in categorical variables were as follows: wild (Core 70 amino acid); TT (rs8099917); n = 13–18 [(TA)n]. Significant P values are shown in bold. The calculated values for serum albumin and T.Bil by multivariate logistic regression analysis correspond to those per 0.1 of increase.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HCV, hepatitis C virus; Hx., history; ISDR, interferon-sensitivity determining region; NVR, non-virological response; PEG-IFN, pegylated interferon; T.Bil, total bilirubin; T.Chol, total cholesterol; VR, virological response; WBC, white blood cell; γGTP, γ-glutamyl transpeptidase.